KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Tax Provisions (2021 - 2026)

Biocryst Pharmaceuticals filings provide 5 years of Tax Provisions readings, the most recent being $2.2 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 170.15% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 83.19% increase, with the full-year FY2025 number at $3.5 million, up 83.19% from a year prior.
  • Tax Provisions hit $2.2 million in Q4 2025 for Biocryst Pharmaceuticals, up from -$769000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.3 million in Q4 2021 to a low of -$1.4 million in Q4 2023.
  • Median Tax Provisions over the past 5 years was $671000.0 (2023), compared with a mean of $632529.4.
  • Biggest five-year swings in Tax Provisions: plummeted 1982.89% in 2023 and later surged 714.53% in 2025.
  • Biocryst Pharmaceuticals' Tax Provisions stood at $2.3 million in 2021, then tumbled by 96.63% to $76000.0 in 2022, then plummeted by 1982.89% to -$1.4 million in 2023, then skyrocketed by 156.18% to $804000.0 in 2024, then surged by 170.15% to $2.2 million in 2025.
  • The last three reported values for Tax Provisions were $2.2 million (Q4 2025), -$769000.0 (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.